C.R. Bard to Acquire Rochester Medical for $262 Million (BCR, ROCM)
C.R. Bard, Inc. (BCR) announced on Wednesday that it will acquire urine drainage care product company, Rochester Medical Corporation (ROCM).
BCR will purchase ROCM for about $262 million, or $20 per share. This acquisition will help BCR expand its urology homecare market. The deal is expected to close later this year.
C.R. Bard shares were mostly flat during pre-market trading Wednesday. The stock is up 17% YTD.
Rochester Medical shares were up $6.04, or 43.74%, during pre-market trading Wednesday. The stock is up 37% YTD.
The Bottom Line
Shares of C.R. Bard, Inc. (BCR) have a 0.73% yield, based on Tuesday’s closing price of $114.66.
C.R. Bard, Inc. (BCR) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars.
Get FREE Dividend Tips, Updates & MoreWe respect your privacy
- Powerful dividend insights sent every weekday morning
- Gain instant access to actionable investing tips
- Strategically grow your portfolio’s profitability